CClinicalTrials.gg
RecruitingNCT06330844Updated Jul 24, 2025

Race-Based Stress and Cognitive Training for MCI

An interventional study of Race Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment (RBSEF-CCT-MCI) and Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT) in Mild Cognitive Impairment, sponsored by Rosalind Franklin University of Medicine and Science. Recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Rosalind Franklin University of Medicine and Science · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

This a two phase project that aims to pilot a new adaptation (Phase 1) of Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT; an originally VA-based cognitive rehabilitation manualized intervention for older adults with MCI, with a focus on the impact of stress on cognitive functioning; that integrates components from the Race Based Stress and Empowerment (RBSE) group for an increased focus on race-based stress and discrimination for racial minority older adults (i.e., RBSEF-CCT-MCI). In a pilot open trial, 75-150 participants will receive group-based intervention for 8 weeks, with 8-10 participants per group.

Following the pilot study, the investigators will complete a randomized controlled trial (RCT) (Phase 2) to compare the efficacy of the RBSEF-CCT-MCI with the ME-CCT. In the RCT, 75-150 participants will be randomized into either 1) The active control group, who will complete the original, ME-CCT training program, or 2) The experimental group, who will complete the newly developed RBSE-CCT-MCI. Both research groups will complete the interventions for 8 weeks, with 8-10 participants per group.

Hypothesis: Participation in this newly developed/updated intervention (i.e., RBSEF-CCT-MCI) will result in improvements in both (a) subjective and (b) objective cognitive functioning, and (c) self-reported mental health symptoms.

Read the detailed description

African American (AA) individuals are at higher risk for non-normative cognitive decline, particularly due to increased rates of cardiovascular and cerebrovascular risk factors. These types of risk factors (e.g., hypertension, diabetes mellitus, obesity, hyperlipidemia, etc.) are independently associated with brain imaging changes, even before potential clinical manifestation of cardiovascular or cerebrovascular disease.

When compared to the general aging population, AA adults experience disproportionately higher rates of hypertension as well as both an earlier age of onset and higher concomitant morbidity and mortality from hypertension when compared to any other racial/ethnic group in the US. AA individuals experience greater exposure to specific chronic stressors, such as discrimination and low socioeconomic status, as well as report higher overall levels of stress compared to white individuals. However, racial disparities in hypertension rates persist even after controlling for socioeconomic status. Researchers have failed to demonstrate any risk factors that are biologically unique to AA patients. These findings have led researchers to consider other psychosocial and environmental factors that may explain the observed hypertension disparities, namely, racial discrimination and racial segregation.

AA older adults are not only at higher risk for non-normative cognitive decline due to both semi-direct (i.e., increased risk of cardiovascular/cerebrovascular risk factors, such as HTN), but other factors such as race-related stress may not only exacerbate these risk factors, but also interfere day-to-day with optimal cognitive performance due to overall increased stress and diversion of cognitive resources. Therefore, for AA older adults, there is an increased need not only for interventions that help to compensate for cognitive decline and increase daily functioning, but also an increased need for an intervention to reduce the effects of race-related stressors. The proposed Race-Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment (RBSEF-CCT-MCI) as proposed in this pilot, is one such intervention that would accomplish those aims and has the potential for a significant impact on patient care for AA older adults who could benefit from additional tools and strategies to improve cognitive functioning and increase day-to-day independent functioning.

Of note, original authors of both protocols have granted consent for modifications of their interventions, and the investigators already have a draft of the new protocol.

02

Conditions studied

  • Mild Cognitive Impairment
03

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The study will be conducted in-person, so they must be able to travel to Rosalind Franklin University.
  • The study will initially be limited to participants who self-identify as Black/African American, or who self-identify with other racial/ethnic groups in addition to self-identifying as Black/African-American; however, may be expanded to include participants that identify as Hispanic/Latine.

Exclusion criteria

Exclusion Criteria:

  • Participants are ineligible to participate in this study if they are not at least 65 years of age and are not experiencing at least mild cognitive impairment or self-reported cognitive difficulties.
  • Participants will also be excluded if they have a diagnosis of dementia (i.e., major neurocognitive disorder), intellectual disability, mild head injury (i.e., concussion) within the last six months, and/or a history of moderate to severe traumatic brain injury.
  • Diagnosis of dementia may be from self-report or other medical records, or for participants to fail screening cognitive assessments (i.e., the RBANS) that would suggest they may be at the level of dementia (i.e., major neurocognitive disorder) as ultimately determined by study PI with objective scores less then 2 standard deviations below the mean on the RBANS.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Experimental: RBSEF-CCT-MCI

    Participants will complete the newly developed RBSE-CCT-MCI training program.

    Behavioral: Race Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment (RBSEF-CCT-MCI)

  • Other
    Control Group: ME-CCT

    Participants will complete the original, ME-CCT training program.

    Behavioral: Motivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT)

Interventions

  • BehavioralRace Based Stress and Empowerment Focused Compensatory Cognitive Training for Mild Cognitive Impairment (RBSEF-CCT-MCI)

    RBSEF-CCT-MCI differs from ME-CCT in that this intervention integrates psychoeducation and strategies for processing and coping with race/ethnicity-related stressors, as part of the larger conversation in ME-CCT regarding stress, and how stress interferes with attention, learning, and subsequently one's subjective sense of memory.

  • BehavioralMotivationally Enhanced Compensatory Cognitive Training for Mild Cognitive Impairment (ME-CCT)

    ME-CCT focuses on: 1. Cognitive training, psychotherapeutic, and lifestyle techniques. 2. Incorporates CCT techniques designed to help patients manage problems with memory, attention, and executive functions (i.e., organization, planning, decision-making, and problem-solving). 3. Includes mindfulness-based stress reduction practice which has been shown to improve cognitive and neuropsychiatric function in various populations.

05

What researchers measure

Primary outcomes

  1. Verbal learning and memory

    Assessed by the California Verbal Learning Test- Second Edition (CVLT-II)

    Time frame: up to eight weeks

  2. Basic auditory attention and working memory

    Assessed by the Digit Span subtest of the Wechsler Adult Intelligence Scale (WAIS-IV)

    Time frame: up to eight weeks

  3. Psychomotor processing speed

    Assessed by the Coding and Symbol search subtests of the WAIS-IV

    Time frame: up to eight weeks

  4. Psychomotor processing speed; executive functioning

    As assessed by the Stroop Test

    Time frame: up to eight weeks

  5. Self-report of prospective and retrospective memory

    The Prospective and Retrospective Memory Questionnaire (PRMQ). The PRMQ developed to provide a self-report measure of prospective and retrospective memory slips in everyday life. It consists of sixteen items, eight asking about prospective memory failures, and eight concerning retrospective failures.

    Time frame: up to eight weeks

  6. Self-report of cognitive concerns

    Neuro-QOL (neuro-quality of life); applied cognition: general concerns \& executive functioning (EF) subscales

    Time frame: up to eight weeks

  7. The Patient Health Questionnaire-9

    (i.e., PHQ-9; assessing self-report symptoms of depression)

    Time frame: up to eight weeks

  8. Self-report symptoms of anxiety

    As assessed by the Generalized Anxiety Disorder-7 questionnaire (i.e., GAD-7)

    Time frame: up to eight weeks

  9. Self-reported daily functioning

    As assessed by The World Health Organization Disability Assessment Schedule 2.0 (i.e., WHODAS 2.0)

    Time frame: up to eight weeks

  10. The Racial Microaggressions Scale

    Assessing the occurrence and distress elicited by racial indignities, slights, mistreatment, or offenses that people of color may face on a recurrent or consistent basis.

    Time frame: up to eight weeks

  11. The Trauma Symptoms of Discrimination Scale

    Self-report measure assessing the traumatizing impact of discrimination broadly by measuring anxiety-related symptoms of trauma due to discriminatory experiences

    Time frame: up to eight weeks

06

Study locations

1 of 1 sites recruiting
  • Rosalind Franklin University of Medicine and Science
    Chicago, Illinois 60064, United States
    • Rachael Ellison, PhD · Contact · 312-940-1718
    • Rachael Ellison, PhD · Principal investigator
    Recruiting
07

References and documents

Publications

  • Huckans M, Hutson L, Twamley E, Jak A, Kaye J, Storzbach D. Efficacy of cognitive rehabilitation therapies for mild cognitive impairment (MCI) in older adults: working toward a theoretical model and evidence-based interventions. Neuropsychol Rev. 2013 Mar;23(1):63-80. doi: 10.1007/s11065-013-9230-9. Epub 2013 Mar 8. PubMed 23471631 ↗
  • Cenat JM. Complex Racial Trauma: Evidence, Theory, Assessment, and Treatment. Perspect Psychol Sci. 2023 May;18(3):675-687. doi: 10.1177/17456916221120428. Epub 2022 Oct 26. PubMed 36288462 ↗
  • Mahdy Ali K, Wonnerth A, Huber K, Wojta J. Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities. Br J Pharmacol. 2012 Nov;167(6):1177-94. doi: 10.1111/j.1476-5381.2012.02081.x. PubMed 22725625 ↗
  • Anazodo UC, Shoemaker JK, Suskin N, Ssali T, Wang DJ, St Lawrence KS. Impaired Cerebrovascular Function in Coronary Artery Disease Patients and Recovery Following Cardiac Rehabilitation. Front Aging Neurosci. 2016 Jan 5;7:224. doi: 10.3389/fnagi.2015.00224. eCollection 2015. PubMed 26779011 ↗
  • Spruill TM, Butler MJ, Thomas SJ, Tajeu GS, Kalinowski J, Castaneda SF, Langford AT, Abdalla M, Blackshear C, Allison M, Ogedegbe G, Sims M, Shimbo D. Association Between High Perceived Stress Over Time and Incident Hypertension in Black Adults: Findings From the Jackson Heart Study. J Am Heart Assoc. 2019 Nov 5;8(21):e012139. doi: 10.1161/JAHA.119.012139. Epub 2019 Oct 16. PubMed 31615321 ↗
  • Dolezsar CM, McGrath JJ, Herzig AJM, Miller SB. Perceived racial discrimination and hypertension: a comprehensive systematic review. Health Psychol. 2014 Jan;33(1):20-34. doi: 10.1037/a0033718. PubMed 24417692 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT06330844
Lead sponsor
Rosalind Franklin University of Medicine and Science
Responsible party
Rachael Ellison (Principle Investigator, Rosalind Franklin University of Medicine and Science) — Principal investigator
First posted
Mar 26, 2024
Start date
Mar 1, 2025
Primary completion
Sep 15, 2027 (estimated)
Completion
Mar 15, 2028 (estimated)
Last update
Jul 24, 2025

Study contacts

Rachael L Ellison, PhD
Contact
rachael.ellison@rosalindfranklin.edu
(847) 578-3000
Rachael L Ellison, PhD
principal investigator · Rosalind Franklin University of Medicine and Science

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion